Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and older~* Diagnosis of schizophrenia or schizoaffective disorder~* Known to have medication treatment adherence problems as identified by the TRQ (20% or more missed medications in past week or past month)~* Ability to be rated on psychiatric rating scales~* Willingness to take long-acting injectable medication~* Able to provide written, informed consent to study participation~Exclusion Criteria:~* History of allergy or intolerance to haloperidol or haloperidol decanoate~* Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment~* Medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial~* Physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist~* Immediate risk of harm to self or others~* Female who is currently pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAE + LAI (Type: EXPERIMENTAL): Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)

Based on this trial design, predict the completion outcome and termination type (if applicable).